Our body contains cell stores which help us to generate cells which fight cancer. These stores or nodes are present throughout the body.
Macrophage & phagocyte locations
Macrophages and phagocytes are produced by the skin, gut and intestinal Peyer's patches, lungs, blood, bone marrow, connective tissue, lymphoid tissue, spleen, and thymus.
Types of phagocytes
- Skin - macrophages, resident Langerhans cells, dendritic cells, mast cells
- Gut and intestinal Peyer's patches - macrophages
- Lungs - macrophages, monocyes, mast cells, dendritic cells
- Blood - neutrophils, monocytes
- Bone marrow - macrophages, monocytes, sinusoidal cells, lining cells
- Connective tissue - macrophages, monocytes, dendritic cells, histiocytes
- Lymphoid tissue - macrophages, monocytes, dendritic cells
- Spleen - macrophages, monocytes, sinusoidal cells
- Thymus - macrophages, monocytes
Peyer's patches
The nodes in the intestine are most important. These nodes are called Peyer's patches. They are found beneath the basement membrane of the intestinal mucosa. They are a source of macrophages and immunoglobulin A (Ig A) in response to contents of the food a person consumes.
Invaders that invade the human body
- Viruses (viral infection)
- Cancer
Viral infection
(keywords: viral enzymes (nagalases), macrophages, immunity)
When a batch of virus launch an attack on the body, the viruses produce an array of enzymes that weaken the macrophages, rendering them ineffective in fighting off the viruses. This is described as a weakened immune system because the body fails to defend itself and fails to fight off the invading viruses.
Cancer
Cancer cells also produce nagalases which act on macrophages, rendering them weak and inefficient in protecting the body against invading cancer cells. With a weakened immune system, the cancer is able to grow and metastasise.
GcMAF-nagalase loop
- GcMAF (contains Gal-GalNAc)
- Nagalase
GcMAF
GcMAF is Gc Protein-derived Macrophage Activating Factor. GcMAF is a glycosylated protein bound to vitamin D. There are three forms (subtypes) of GcMAF. They differ in the number of sugar and sialic acid residues in the side chain. The sugar found in GcMAF are glycosamines.
Structure of Gc protein
The Gc protein contains a threonine (Thr) residue, to which is attached a disaccharide side chain containing galactose (Gal) and Galactosamine (GalNAc) and sialic acid (SA), or simply, Gal-GalNAC-SA. Gal-GalNAC is a cancer biomarker for colon cancer (carcinogenesis). There are three forms of Gc which can be converted to GcMAF. They are Gc1f, Gc1s and Gc2.
(Gc1f): -aa-aa-aa-aa-Thr-aa-aa-
|
Gal-GalNAc
|
SA
Gc1s: -aa-aa-aa-aa-Thr-aa-aa-
|
(SA)-Gal-GalNAc
|
SA
Gc2: -aa-aa-aa-aa-Thr-aa-aa-
|
Gal-GalNAc
Nagalase
Nagalase if one of the viral enzymes. There are two types of nagalases - ie exo- and endo-nagalases. They act at different sies (loci) on GcMAF.
Pathway
When virus or cancer attacks the body, they produce nagalases, which act on macrophages and inactivate them. GcMAF on the other hand, acts opposite of nagalase, ie, they promote macrophage activation. Activated macrophages can transform into natural killer cells (NK cells) which can actively fight a viral infection or cancer.
Production of GcMAF
GcMAF is produced by a laboratory in Japan. There are two productions of GcMAF, ie first and second generations.
- First generation GcMAF (1991-2010)
- Second generation GcMAF (2011-present)
First generation GcMAF
This GcMAF was less concentrated, unstable at room temperature and had a short half-life.
Second generation GcMAF
This GcMAF was more concentrated, more stable and can last two weeks without refrigeration and up to a year with refrigeration. This is the preferred form for use.
Administration routes of GcMAF
GcMAF can be administered via four routes, ie, skin, muscle, intestine and lungs.
- Skin (subcutaneous, SC)
- Muscle (intramuscular, IM)
- Intestine (oral)
- Lungs (inhalation via nebulizer)
Conversion of Gc1f to GcMAF
- B cells contain lyso-PC inducible beta-galactosidase. This enzyme removes galactose from the Gal-GalNAc side chain.
- T cells contain sialidase. This enzyme removes sialic acid from the GalNAc-SA side chain.
GcMAF: -aa-aa-aa-aa-Thr-aa-aa-
|
GalNAc
Macrophage activation and transformation
GcMAF acts on dormant macrophages to activate them. Activated macrophages transform to NK cells.
Is GcMAF therapy effective?
YES, in the 99 patients who obtained successful treatment.
NO, in one patient in which treatment failed.
Failure rate is 1 in 100 or 1% ineffectiveness, which is negligible.
https://www.immunotherapy-cancer-and-chronic-disease.com/frequently-asked-questions-about-second-generation-gcmaf/
http://gcmaf.timsmithmd.com/book/chapter/53/
https://www.advancedrejuvenationinstitute.com/cancer/3-immunotherapy/cancer-research-gcmaf.html
https://healingoracle.ch/2017/09/06/tutorial-how-to-inject-gcmaf/
https://www.researchgate.net/figure/Plasticity-of-macrophages-in-tumor-microenvironment-and-pathogenesis-of-HCC_fig2_275041931
https://www.immunopaedia.org.za/clinical-cases/infectious-diseases/a-case-of-decreased-joint-function-fever-and-rash/
http://cancerres.aacrjournals.org/content/76/3/513/F1
https://healingoracle.ch/2017/09/06/tutorial-how-to-inject-gcmaf/
https://cancer-cures-plus.com/persecuted-heroes/how-gcmaf-works/new-cancer-fighter-gcmaf-update/
https://thetruthaboutcancer.com/gcmaf/
http://www.brainimmune.com/endogenous-catecholamines-in-immune-cells-discovery-functions-and-clinical-potential-as-pharmacotherapeutic-targets-3/
https://immuno-oncologynews.com/2015/06/09/pd-1-protects-t-cells-burning/
https://www.ncbi.nlm.nih.gov/pubmed/8839767
0 comments:
Post a Comment